Bristol Myers Squibb Raises Full-Year Guidance Following Strong Q2 Earnings
Bristol Myers Squibb (NYSE:BMY) reported second-quarter results that exceeded Wall Street expectations, driven by strong performance from its growth portfolio. The pharmaceutical company raised its full-year financial outlook for both revenue and earnings per share as a result of the stronger-than-expected sales. The Growth Portfolio generated $7.6 billion in revenue during Q2 2026, up 15% year-over-year excluding currency effects. Key drivers included products like Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, and Opdualag. However, the Legacy Portfolio saw a decline due to ongoing generic competition. Bristol Myers Squibb now expects adjusted earnings per share between $6.75 and $7.00 for 2026—up from previous guidance—and revenue of $49.5 billion to $50.0 billion, surpassing analyst expectations.
Tickers: $BMY